Drug Type Small molecule drug |
Synonyms THRV-1257, THRYV1257 |
Target |
Mechanism SGK1 inhibitors(SGK-1 protein kinase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization Thryv Therapeutics, Inc.Startup |
Active Organization Thryv Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anaplastic Thyroid Carcinoma | Phase 1 | - | Thryv Therapeutics, Inc.Startup | - |
Thyroid Cancer | IND Approval | US | Thryv Therapeutics, Inc.Startup | 15 Aug 2023 |
Colorectal Cancer | Preclinical | CA | Thryv Therapeutics, Inc.Startup | 11 Mar 2024 |
MAPK mutation Solid Tumors | Preclinical | CA | Thryv Therapeutics, Inc.Startup | 11 Mar 2024 |
Diffuse Large B-Cell Lymphoma | Preclinical | CA | Thryv Therapeutics, Inc.Startup | 13 Apr 2023 |
Breast Cancer | Preclinical | CA | Thryv Therapeutics, Inc.Startup | 06 Dec 2022 |
Prostatic Cancer | Preclinical | CA | Thryv Therapeutics, Inc.Startup | - |